Alchem Laboratories Corporation

Dedicated to excellence in custom synthesis

James D. Talton, Ph.D., is the President and CEO of Alchem Laboratories Corporation. Prior to joining Alchem, Dr. Talton served as the President and Chief Executive Officer of Nanotherapeutics, Inc. for seventeen years. He also is President of Nanopharmaceutics, Inc., President of Discovery Cure Institute, Inc., a Florida non-profit Corporation and serves on the Alumni Advisory Board for the University of Florida Department of Materials Science and Engineering. Dr. Talton has developed multiple clinical-stage products as well as NanoFUSE® DBM, a sterile, FDA-cleared (K062459) easy-to-reconstitute bone graft. Leading multiple successful government programs, Dr. Talton has successfully won over $1 billion in contracts with government partners including NIH, DOD, and BARDA. Dr. Talton is an inventor on eleven U.S. patents and has authored several peer-reviewed publications and book chapters involved in drug delivery systems with a primary focus in drug analysis and controlled release formulations, pharmacokinetics, and pulmonary drug delivery. Dr. Talton received his B.S. and M.S. in Materials Science and Engineering and his Ph.D. in Pharmaceutical Sciences from the University of Florida.


Judy Talton, MS, ARNP, is the Chief Operating Officer at Alchem.  Judy received her MS in Nursing in 2009 from University of Florida and is board certified in Acute Care and Family Practice.  Prior to her medical career, Judy had positions in real estate, marketing, and management.


Steve Vasile, Ph.D. is Alchem’s Director of Discovery overseeing assay development and high throughput screening (HTS). He received his Ph.D. in biochemistry from the State University of New York at Buffalo’s Roswell Park Cancer Institute division in 1993. Dr. Vasile has over 25 years of experience in the HTS field, with significant experience with multiple assay formats and with diverse screening laboratory instrumentation and automation. Dr. Vasile was recruited in 2018 from Sanford Burnham Prebys Medical Discovery Institute where he was Director of HTS for their Orlando, FL site. Prior to SBP he was at Sugen Inc./Pharmacia/Pfizer. At Sugen his team helped to discover Sutent, an FDA-approved drug for renal cell carcinoma, Gleevec resistant GIST and advanced pancreatic neuroendocrine tumors.

Otto Geoffroy, Ph.D. is Alchem's Director of Research.   He is responsible for most laboratory-scale synthetic projects.  He received his Ph.D. in organic chemistry from Tulane University in 1992.  Following this he was an NIH post-doctoral fellow in the Department of Pharmaceutical Sciences at the Medical University of South Carolina (1992-1994) and a post-doctoral fellow at the Hollings Cancer Center (1995-2000). Dr. Geoffroy joined Alchem in 2001 as a Senior Scientist and Group Leader.  He was promoted to Director of Research in 2009.

Sergiy Denysenko, Ph.D. is Alchem's Director of Manufacturing. He oversees the scale-up laboratory and GMP manufacturing projects.  Sergiy joined Alchem in 2001 as a Senior Research Scientist and was promoted to Principal Research Scientist in 2004 before becoming Director of Development in 2009. He received his Ph.D. in synthetic organic chemistry from Moscow State University in 1985.   Following this he was Associate Professor at the Ukrainian State University of Chemical Technology (1985-1996) and a Postdoctoral Fellow and Senior Group Leader with Professor Alan Katritzky's research group at the University of Florida (1996-2001).

Vladimir Rudchenko, Ph.D. is  Alchem's Technical Director.  His extensive background spans more than three decades in research and industry.  Dr. Rudchenko joined Alchem in 2001 and provides technical direction to both the Research and the Development groups.  His academic credentials include D.Sc. in organic chemistry (Institute of Organic Chemistry, Academy of Sciences of the USSR, Moscow, 1986), Ph.D. in synthetic organic chemistry (Institute of Organic Chemistry, Academy of Sciences of the USSR, Moscow, 1977), and B.Sc. (with Distinction) in chemical engineering (Institute of Chemical Technology, Dnepropetrovsk, Ukraine, 1973). Dr. Rudchenko is an author of 13 patents and over 70 publications.

Jing Yang, Ph.D. is  Alchem's Director of Quality Control.  She received her undergraduate training in analytical chemistry at Shanghai University and a Ph.D in organometallic chemistry from the University of Florida. Joining Alchem in 1999 Dr. Yang was first responsible for API synthesis and process development and was promoted in 2001 to Group Leader for process development and GMP manufacturing of late-stage-experimental products. She was appointed to her current position in 2006.


Ray Malloy, M.S. is Alchem's Acting Director of Quality Assurance.  He completed his undergraduate and graduate studies (Masters of Science) at the University of South Florida, Tampa. He worked as an Environmental Scientist, being involved with analysis of water quality samples, pollution incident investigations, management of quality control database, and quality assurance review at the Environmental Protection Commission of Hillsborough County, Tampa, FL. Mr. Malloy joined Pharmos Corporation in 1994 as a Research Chemist. He was then involved with regulatory affairs and quality assurance issues as a consultant. He was in charge with cGMP manufacturing at Pharmos followed by Alchem twenty years ago and has directed Quality Assurance for over ten years.

Charles Alligood, A.S. is  Alchem's Facilities Manager.  After serving four years in the United States Coast Guard, Mr. Alligood has overseen pharmaceutical R&D facilities since 1987 and has an extensive background in instrument maintenance and hazardous waste management.